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Abstract
Background: A long-standing epidemiological puzzle is the reduced rate of rheumatoid
arthritis (RA) in those with schizophrenia (SZ) and vice versa. Traditional epidemiological
approaches to determine if this negative association is underpinned by genetic factors
would test for reduced rates of one disorder in relatives of the other, but sufficiently pow-
ered data sets are difficult to achieve. The genomics era presents an alternative paradigm
for investigating the genetic relationship between two uncommon disorders.
Methods: We use genome-wide common single nucleotide polymorphism (SNP) data
from independently collected SZ and RA case-control cohorts to estimate the SNP correl-
ation between the disorders. We test a genotype X environment (GxE) hypothesis for SZ
with environment defined as winter- vs summer-born.
Results: We estimate a small but significant negative SNP-genetic correlation between SZ
and RA (0.046, s.e. 0.026, P¼ 0.036). The negative correlation was stronger for the SNP
set attributed to coding or regulatory regions (0.174, s.e. 0.071, P¼0.0075). Our analyses
led us to hypothesize a gene-environment interaction for SZ in the form of immune chal-
lenge. We used month of birth as a proxy for environmental immune challenge and esti-
mated the genetic correlation between winter-born and non-winter born SZ to be signifi-
cantly less than 1 for coding/regulatory region SNPs (0.56, s.e. 0.14, P ¼ 0.00090).
Conclusions: Our results are consistent with epidemiological observations of a negative
relationship between SZ and RA reflecting, at least in part, genetic factors. Results of the
month of birth analysis are consistent with pleiotropic effects of genetic variants depend-
ent on environmental context.
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Introduction
A long-standing epidemiological puzzle is the reduced
prevalence of rheumatoid arthritis (RA) in those with
schizophrenia (SZ) and vice versa. First identified nearly
80 years ago, it has been reported in nearly every observa-
tional study of the incidence of the two disorders. A meta-
analysis1 of nine studies found that risk of RA in SZ
subjects was less than 29% of the risk in the general popu-
lation. Under-reporting of somatic disease in those with se-
vere psychiatric conditions may be a contributing factor,2
but the prevalence of RA is not reduced in those with other
psychiatric disorders.1 Surprisingly, the reduced preva-
lences are observed despite the high prevalence of smoking
in SZ [odds ratio (OR)¼ 5.3],3 which is an established risk
Key Messages
• The proportion of variance in liability attributable to common SNPs is 0.223 (s.e. 0.006) for schizophrenia and 0.194
(s.e. 0.007) for rheumatoid arthritis.
• The MHC region is proportionally more important for rheumatoid arthritis than for schizophrenia; after excluding this
region, the proportion of variance attributable to common SNPs is reduced to 0.212 (s.e. 0.006) for schizophrenia and
0.137 (s.e. 0.007) for rheumatoid arthritis, respectively.
• The epidemiological observations of a negative relationship between SZ and RA reflects, at least in part, genetic
factors.
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factor for RA in general population samples (OR>2).4
Both disorders have similar lifetime risk (1%), a waxing
and waning pattern of symptoms and increased mortality.
On the other hand, there are also dissimilarities including
age at onset (16–30 years in SZ vs 25–55 years in RA)5 and
male:female ratio (nearly 3 females to 1 male for RA5 and
1 female to 1.4 males for SZ6). Sex differences were not
considered in early studies of the SZ-RA relationship, but
recent population-based studies from Sweden2 and
Denmark7 accounted for age and sex differences and still
reported reduced risks of RA in SZ compared with those
without SZ.
Both SZ and RA have a strong genetic component to
their aetiology. For both, heritabilities estimated from na-
tional hospital records (SZ 64%8 and RA 40%9) are lower
than estimates from twin studies (SZ 81%10 and RA
60%11). RA has two distinct subtypes classified on the
presence (seropositive) or absence (seronegative) of anti-
bodies to citrullinated protein antigen. Approximately
two-thirds12 of cases are seropositive, and of seronegative
cases 4–11% have been estimated to reflect misdiagnosis
(for example of ankylosing spondylitis) and 15–37% have
been estimated to be undetected seropositive.13 Using na-
tional data from Sweden, the heritability of seropositive
RA was estimated as 50% compared with 20% for
seronegative RA.9
A number of hypotheses have been proposed to explain
the SZ-RA protective relationship,14 including abnormal
tryptophan metabolism,15 prostaglandin deficiency,16–18
an imbalance in corticosteroids,19 psychosocial factors14
or consequence of medication.1 Definitive evidence to sup-
port these hypotheses is lacking. There is evidence that fac-
tors influencing immune activation, including
environmental insults such as infectious agents, are poten-
tial pathogenic mechanisms for both disorders.5,20 For ex-
ample, both RA and SZ have been linked, albeit with some
controversy, to increased rates of infection by viruses such
as Epstein-Barr virus and the parasite Toxoplasma gondii
(for a review see5). SZ is considered to be a neurodevelop-
mental disorder, and immune activation in early life may
be of particular importance, consistent with perinatal risk
factors21 such as infection and month of birth.22 RA is an
autoimmune disorder, and it has been suggested that there
is an autoimmune component to SZ.23,24 The autoimmune
theory of SZ is supported by epidemiological evidence
showing that whereas the relationship between SZ and RA
is a negative one, the risk of many other autoimmune dis-
orders is higher in SZ than in controls.7,25,26 An analysis of
Danish national records showed a dose-response relation-
ship between risk of SZ and hospitalizations for infection
and autoimmune disorders, where three or more infections
and an autoimmune disease were associated with an
incidence rate ratio of 3.40 [95% confidence interval (CI)
2.91–3.94].27 As for all autoimmune disorders,28 the major
histocompatibility complex (MHC) plays an important
role in RA29,30 but with different alleles being associated
with seropositive cases compared with seronegative
cases.13 A role for the MHC in the aetiology of SZ has
been proposed for decades,31 but the empirical evidence
has been less consistent than for RA. The first large gen-
ome-wide association studies (GWAS) for SZ identified the
MHC locus as the most strongly associated locus.32–34
Using the latest published GWAS results,35,36 the MHC
locus is the only locus that reaches genome-wide signifi-
cance for both SZ and RA. The most associated single nu-
cleotide polymorphism (SNP) for RA is associated with SZ
and vice versa; contrary to expectation, given the negative
SZ-RA association, the associated alleles are the same for
the two disorders, albeit stronger for RA than SZ (Box 1).
This unexpected result may reflect the well-recognised
complexity of the MHC region.37 The primary association
for rheumatoid arthritis is within HLA-DRB1 in the class
II MHC region, and has a large effect relative to the more
modest and less clearly localized effect in schizophrenia. It
may be the case that the role of HLA-mediated antigen rec-
ognition is simply different in the two diseases, playing a
dominant role in rheumatoid arthritis and perhaps a more
modest or absent role in schizophrenia. If the negative as-
sociation between RA and SCZ reflects genetic factors,
then it may be driven predominantly by non-HLA genetic
factors that are related to immune activation rather than
antigen recognition. Genome-wide significant variants ex-
plain 3.4% of the variance in liability to schizophrenia and
11.4% of the variance in liability of RA (Box 1). Genome-
wide polygenic methods38,39 have estimated that for SZ,
23%40 of the variance in liability is attributable to com-
mon SNPs (or SNP heritability), and 14%41 to 18%39 for
RA excluding the contribution from the MHC region
(5%). These results imply that more associated loci will
be identified for each disorder as sample size increases.
Given the substantial genetic contribution to both dis-
orders, can the negative association between SZ and RA be
attributed to genetic factors? This can be investigated from
traditional epidemiological studies by measuring risk of
RA in relatives of those with SZ compared with relatives of
control subjects, and vice versa. As RA and SZ are rela-
tively uncommon, very large cohorts of families with mul-
tiple family members measured for both disorders are
needed, and this has not been achievable through the fam-
ily study framework from which estimates of heritability
are traditionally derived. National databases provide the
only viable strategy to explore a genetic relationship
through traditional epidemiological methods, but few
countries have suitable national recording frameworks.
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Box 1. Comparison of GWAS results of SZ36 and RA.35
a. MHC locus. Odds ratios for the two most highly associated SNPs for SZ, rs115329265 (aka rs1233578, hg19:chr 6:
28 712 247 bp), RAF¼0.85 and for RA, rs9268839 (aka rs116633882, hg19:chr 6: 32 428 772 bp) RAF¼ 0.45. Both are
located in the MHC region and the LD r2 of these SNPs is zero. We note that the RA allele tags the HLA DRB-1 allele,
but that the SZ allele is not associated with any classical HLA allele, although it is reported36 to be in LD r2¼ 0.32 with
an eQTL SNP for HLA-A. The association P -values are listed above the error bars.
b. Variance explained by genome-wide significant (GWS) loci, reported as associated at P<5e-8.
• For SZ 128, statistically independent GWS loci are reported.36 Together these explain 3.4% of the variance in liabil-
ity (calculated from reported RAF and OR using INDI-V71 assuming lifetime risk of 1%); all SNPs associated with
P<0.05 explain 7% of variance in out of sample prediction.36 Of these 128 SNPs, 102 could be matched to GWAS
results for RA. The minimum P-value in RA of a SZ GWS locus was 0.004.
• For RA, 101 independent GWS loci are reported.35 Together these explain 11.4% of the variance in liability (using
INDI-V71 assuming lifetime risk of 0.7%). All SNPs could be matched to GWAS results for SZ. The minimum
P-value in SZ of an RA GWS locus was 2.06e-05 (see MHC locus above).
c. QQ plots: (i)- P-values from SZ GWAS for 101 RA GWS loci; (ii) P-values from RA GWAS for 102 SZ GWS loci.
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A Danish national study25 compared 7704 persons in
Denmark diagnosed with SZ and their parents with a sam-
ple of matched subjects and their parents. Contrary to a
hypothesis of a negative genetic association, this study
found significantly increased rates of RA in parents of those
with SZ compared with parents of control subjects. A
Swedish national study reported that first-degree relatives of
schizophrenia patients were not at reduced risk of RA, but
the risk for seronegative RA was significantly decreased in
children and siblings of SZ probands [hazard ratio
(HR)¼ 0.13; 95% CI 0.02–0.95, and HR¼ 0.67; 95% CI
0.50–0.91, respectively].2 These studies assumed that risk in
first-degree relatives is only attributable to genetic factors,
but sharing of environmental factors could also contribute.
The genomics era provides a new opportunity to investi-
gate whether the SZ-RA relationship may be attributable
to genetic factors, by determining whether common alleles
conferring increased risk to SZ are protective against RA
and vice versa. The hypothesis has been considered for can-
didate genes outside the MHC region, but no shared asso-
ciations were found.42,43 Comparison of the latest GWAS
results for SZ36 and RA35 shows evidence for more associ-
ation of the genome-wide significant (GWS) loci from each
disease in the other disease than expected by chance
(Box 1). Across GWS SNPs, there is a positive correlation
between the OR of the two disorders (Box 1), although
this relationship is dominated by the positive correlation
between SNPs in the MHC region described above.
Here we use linear mixed model methods, applied to
genome-wide SNPs from case-control cohorts collected for
GWAS, to explore the relationship between SZ and RA.44
By comparing additive genetic similarities between SZ and
RA cases with their genetic similarities with controls, we
quantify the relationship between the disorders by the
SNP-genetic correlation.44,45 Since this approach uses un-
related cases and controls to estimate the SNP correlation,
estimates are less likely to be confounded with shared en-
vironmental factors that can bias estimates from family
studies or population studies where individuals are meas-
ured for both phenotypes. We use this framework to ex-
plore the genetic relationship between SZ and RA.
Methods
Data
Three RA and two SZ GWAS data sets (see Supplementary
Table 1, available as Supplementary data at IJE online)
were made available to us. Briefly, the Stahl et al. (‘Stahl’)
RA sample comprises 5441 seropositive cases and 22 532
controls of European ancestry from six independent case-
control cohorts.39,46 The Okada et al. (‘Okada’) RA sam-
ple has 3427 cases (1840 seropositive) and 6837 controls
of European descent from five independent case-control
cohorts,35 including the Corrona RA cohort. The
Epidemiological Investigation of Rheumatoid Arthritis
(EIRA) sample comprises 770 seronegative RA cases
(EIRA seropositive cases from this cohort were already
included in the Stahl sample). The Psychiatric Genomics
Consortium (PGC) for Schizophrenia Wave 1 sample com-
prises data from 17 GWAS cohorts47 and a total of 9431
cases and 12 848 controls; and the Swedish (SWE) sample
d. OR plots: (i) RA GWS loci (correlation 0.35, P¼ 4.0e-4, becomes non-significant if SNPs with the two largest OR are
excluded); (ii) SZ GWS loci (correlation 0.24, P¼ 0.015, which becomes non-significant if the MHC SNP is excluded).
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comprises 5193 case and 6391 controls48 in four cohorts
defined by genotyping platform which were independent
of Swedish samples in PGC. All sample sizes are those after
sample quality control (QC).
All data sets were processed through similar QC and
imputation pipelines47 using the CEUþTSI Hapmap
Phase 3 data as the reference panel. We augmented these
QC so that estimates of genetic variance would not be
influenced by artefacts of genotyping.38 SNPs with an im-
putation r2> 0.6 and an MAF> 0.01 in all cohorts were
retained, resulting in 797 875 SNPs for analysis. Sex
chromosome data were not available for all data sets and
so were excluded. If any pair of individuals had an esti-
mated similarity relationship coefficient49>j0.05j, one per-
son was excluded at random so that all SZ cases, RA cases
and controls were unrelated. The final analysis data set
consisted of 8064 seropositive RA cases (including 1131
RA cases of unknown status of which at least two-
thirds12,13 are expected to be seropositive), 1197 seronega-
tive RA cases and 26 737 controls plus and 12 793 SZ cases
and 15 912 controls (Figure 1). Given accumulating evi-
dence that seropositive and seronegative RA should be re-
garded as different clinical entities,13 we did not combine
seropositive and seronegative RA cases.
SNP heritabilityand SNP genetic correlation
The bivariate linear mixed model genomic relationship ma-
trix (GRM) restricted maximum likelihood (GREML) ap-
proach44 implemented in GCTA50 was used to estimate
SNP heritabilties, the SNP coheritability and the SNP cor-
relation between the disorders. The standard error (s.e.) of
each estimate was calculated by the delta method51 which
has been shown to agree well with s.e. expected from nor-
mal distribution theory.52 We used the estimate and its s.e.
to generate a Wald statistic to test hypotheses that SNP
heritabilities were different from zero and that SNP correl-
ations were less than zero; the directional hypothesis for
the correlation is justified by the epidemiological data re-
ported in the Methods section. The model of analysis esti-
mates SNP heritabilities as the proportion of variance in
case-control status attributable to genome-wide SNPs, but
estimates of SNP heritabilites and coheritabilities are pre-
sented on the liability scale,38,44 assuming population life-
time risk of 1% for SZ, 0.7% for seropositive RA and
0.3% for seronegative RA, so that they can be compared
with estimates from epidemiological data. We note that
when genetic relationships between individuals are small,
the relationship between disease and liability scale is ap-
proximately linear and so the estimated genetic correlation
is independent of scale.44 A SNP correlation of zero is esti-
mated if the genome-wide relationship between cases of
one disorder is the same with the cases as with the controls
of another disorder. A SNP correlation reflects the magni-
tude of the covariance term between the traits relative to
the product of the standard deviations, and so can be high
even when the covariance is low. A genome-wide SNP cor-
relation could represent a uniform correlation across the
genome or a weighted average of higher and lower correl-
ations. Hence, we undertook genomic partitioning analyses
which included multiple additive genetic random effects
terms in the linear mixed model with multiple GRM con-
structed from non-overlapping SNP sets.45,49 Cohort and
the first 20 principal components were included as covari-
ates in all analyses. Sex was included as a covariate for SZ
and in some analyses for RA. SNP heritabilities are pre-
sented on the liability scale. Follow-up analyses were con-
ducted by sex and considering functional annotation.
Sensitivity analysis
We explored the sensitivity of our results and sought to ex-
clude the possibility that genetic outliers could explain our
results. We tested this by restricting the coefficient of simi-
larity between any pair of individuals to be< j0.025j. As
one individual from a pair was excluded at random, we
constructed 20 randomly drawn samples with restricted
ancestry, and drew 20 random samples of the same size
from the sample with coefficient of similarity< j0.05j.
Benchmarking with epidemiological
observations
From epidemiological studies we can obtain estimates of
the population risk of SZ and RA, KSZ and KRA,
Figure 1. Sample sizes.
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respectively, and also for the probability of RA in those
with SZ, KRAjSZ. We assume that the phenotypic liabilities
of SZ (lSZ) and RA (lRA) are distributed as bivariate normal
with mean 0, standard deviation 1 and correlation RSZRA:
V
lSZ
lRA
 !
¼
VðlSZÞ CovðlSZ; lRAÞ
CovðlSZ; lRAÞ VðlRAÞ
" #
¼
1 RSZRA
RSZRA 1
" #
The variances and covariance of liabilities among those af-
fected with SZ
V
lSZjDSZ
lRAjDSZ
 !
¼ ¼
1  kSZ RSZRAð1  kSZÞ
RSZRAð1 kSZÞ 1 R2SZRAkSZ
" #
where ksz¼ isz(isz–tsz) and reflects the proportional vari-
ance reduction as a consequence of ascertainment on SZ
status,50,51 with meanðlSZjDSZÞ ¼ iSZ ¼ dSZKSZ , with dsz the
height of the normal curve at the threshold tsz defined from
Pðz > tSZÞ ¼ KSZ. From KRAjSZ we define the normal dis-
tribution threshold53,54 for RA in those with SZ as
tRAjSZ ¼ tRAiSZRSZRAﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1kszR2SZRA
p
Solving the quadratic for RSZRA gives
RSZRA ¼
iSZtRA 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
i2SZt
2
RA  ðt2RAjSZ þ i2SZÞðt2RA  t2RAjSZÞ
q
ðt2RAjSZ þ i2SZÞ
(equation 1)
Genotype x environment analysis
Our analyses led us to a postulate a hypothesis of genotype
x environment interaction for SZ. Specifically we hypothe-
sized that the SNP correlation would be less than 1 for cod-
ing and regulatory SNPs in a bivariate analysis in which the
two traits are winter-born and non-winter born SZ cases
and controls. We undertook a bivariate GREML analysis to
test this hypothesis. Month of birth was only available for
the SWE SZ sample, which comprised winter-born cases
(born January to April22, n¼ 1511) and winter-born con-
trols (n¼ 2036), as well as non-winter cases (n¼ 2962) vs
non-winter controls (n¼ 3772); 199 individuals did not
have month of birth recorded. To visualize the interaction,
we identified 47318 SNPs associated with schizophrenia36
at P< 0.05 (the threshold that maximized out of sample pre-
diction across multiple cohorts;36 the SNPs were quasi-inde-
pendent with minor allele frequency> 0.05, pairwise
linkage disequilibrium r2< 0.25 in a 250-kb window). We
identified the risk alleles of the SNPs that defined the odds
ratio to be greater than 1. We undertook association analysis
(logistic regression with 20 principal components, cohort
and sex as covariates) in the Swedish sample that had season
of birth recorded. We estimated the OR of the risk alleles
and compared mean OR for SNPs annotated as C&R (cod-
ing/regulatory, the genomic region showing strong negative
SNP correlation between SZ and RA, 2820 SNPs, 6%) and
not coding/regulatory, testing the hypothesis H0: Mean OR
for winter-born sample¼Mean OR for other sample.
Results
SNP heritability and SNP genetic correlation
The estimated SNP heritability for RA seronegative cases
was indistinguishable from zero (0.006, s.e. 0.025,
P¼ 0.98). Despite the smaller sample size for seronegative
cases, the s.e. shows that it was powered to detect SNP her-
itability> 5%. Given there was no evidence of contribu-
tion to risk of common variants for this sample, detection
of a genetic relationship between these cases and SZ was
not possible. Hence, all reported analyses are for seroposi-
tive RA cases only. Given the major contribution of the
MHC region in RA (which may violate underlying assump-
tions of GREML55,56), we undertook analyses using as the
phenotype residuals after adjusting for the 550 SNPs (the
number after pruning for SNPs with linkage disequilbrium
r2> 0.99) located within the MHC region (29–34Mb in
chromosome 6) and for the other covariates. For SZ, the
estimated SNP heritabilities were 0.223 (s.e. 0.006) includ-
ing the MHC region and 0.212 (s.e. 0.006) after correcting
for the MHC region. For RA, the estimated SNP heritabil-
ities were 0.194 (s.e. 0.007) including the MHC region and
0.137 (s.e. 0.007), after correcting for the MHC region.
The estimated SNP genetic correlations were 0.046 (s.e.
0.026) and 0.065 (s.e. 0.030) for including the MHC and
after correcting for the MHC, respectively, which were sig-
nificantly less than zero (P-values¼ 0.036 and 0.015, re-
spectively) (Figure 2; Supplementary Table 2, available as
Supplementary data at IJE online). We confirmed that the
method to estimate P-values was robust, by checking the
P-value from a likelihood ratio test comparing models with
and without genome-wide SNP effects.
To aid interpretation and comparisons, we also present
the SNP genetic covariance or coheritability, the latter rep-
resents the relationship between the disorders on the same
scale as the heritability (Supplementary Table 2). Subset
analyses (PGC-SZ/Stahl-RA, PGC-SZ/Okada-RA, SWE-
SZ/Stahl-RA and SWE-SZ/Okada-RA) showed negative
genetic correlations estimated for all combinations except
PGC-SZ/Stahl-RA (Figure 2, Supplementary Table 2). We
explored the sensitivity of our results and sought to exclude
the possibility that genetic outliers could explain our results
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(see Methods). We found that the SNP correlation between
SZ and RA was significantly (P¼ 0.0049) more negative in
20 samples drawn from our data when ancestry was more
restricted (similarity relatedness coefficient< j0.025j)
[0.054, standard deviation over replicates (s.d.) 0.002 vs
0.047 s.d. 0.001] (Supplementary Figure 1). This sensitiv-
ity analysis implies that the negative correlation is not driven
by ancestry artefacts and provides confidence that SNP cor-
relation between SZ and RA is negative.
Sex analyses
Given that risk of RA is higher in females and risk of SZ is
higher in males, we undertook SZ/RA analyses stratified
by sex (i.e. four-trait multivariate GREML, in which the
four traits were SZ-male, SZ-female, RA-male, RA-female
each matched by their sex-specific control set) to determine
if SNP correlations (based on autosomal SNPs) were sex
dependent. Sex information was missing for 11% of the
RA sample who were excluded in the analysis. Based on re-
ported male:female population ratios,5,6 we assumed the
male and female baseline risks were 0.42% and 0.98% for
seropositive RA, and 1.15% and 0.85% for SZ respect-
ively. SNP heritabilities were significantly greater when
estimated from males compared with females for SZ (male
0.258, s.e. 0.010, female 0.214, s.e. 0.012, P¼0.0053) but
not for RA (male 0.174, s.e. 0.016, female 0.158, s.e.
0.013, P¼ 0.43) (Figure 2, Supplementary Table 2); these
estimates must be interpreted with caution, recognizing
that they are dependent on the lifetime risk of disease
chosen for each sex. SNP correlations between sexes were
high but were significantly different from 1 for both RA
(P¼ 6.1e-06) and SZ (P¼2.4e-07, Supplementary
Table 2). All SNP correlation point estimates are negative
between male/female SZ/RA analyses.
Functional annotation analyses
Previous studies40,41,57 have demonstrated that contributions
to SNP heritabilities are not distributed equally over the gen-
ome. We therefore set out to test if the SNP-correlation
between SZ and RA was dependent on SNP annotation.
We undertook genomic partitioning analyses in which
multiple additive genetic random effects terms were con-
sidered in the linear mixed model,45,49 with multiple GRM
each constructed from SNPs grouped by a functional anno-
tation. Following Gusev et al.,57 SNPs were classified as
being in coding/regulatory (in exons, 3’ UTR, 5’UTR, 1-kb
region up- and downstream of transcription start and end
site and noncoding RNA), DNase I hypersensitivity sites
(DHS) and intronic or intergenic regions. SNPs with mul-
tiple annotations were allocated with hierarchical prefer-
ence of coding/regulatory, over DHS and over intronic. For
SZ, all annotations had estimates of SNP heritability that
were significantly greater than zero (Figure 3;
Supplementary Table 3, available as Supplementary data
at IJE online), although the proportion of total variance
allocated to intergenic SNPs was significantly less than ex-
pected given the proportion of all SNPs annotated to that
group (Figure 3; Supplementary Table 3). For RA, the
coding/regulatory and DHS annotations had SNP heritabil-
ity estimates that were both significantly different from
zero and were higher than expected based on the propor-
tion of SNPs in those functional partitions (Figure 3;
Supplementary Table 3). As a consequence in RA, and in
contrast to SZ, neither intronic nor intergenic variants
Figure 2. Genome-wide estimates: (i) SNP heritability; (ii) SNP correl-
ation (using RAþ ve only). Estimates are from analyses using as the
phenotype residuals after adjusting SNPs in the MHC region unless
otherwise stated.
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made a significant contribution to SNP heritability, a find-
ing that is underscored by the fact that the proportion of
all SNP heritability contributed by these types of variant is
significantly less than expected based upon the proportion
of SNPs of these classes. Given that in RA, SNP heritability
is essentially restricted to SNPs in coding/regulatory and
DHS regions, these are the only classes of SNP for which
meaningful estimates of SNP correlation between SZ and
RA can be made. We note that currently available DHS an-
notation may be biased towards cell types of relevance to
RA compared with SZ. We estimated a significant and
stronger genetic correlation for coding/regulatory region
regions (0.322, s.e. 0.115, P¼0.003) (Figure 3;
Supplementary Table 3) than for the whole genome.
Immune related pathway analyses
Since RA is an autoimmune disease and since the epi-
demiological negative relationship between SZ and RA
has contributed to the autoimmune hypothesis of SZ, we
set out to test if the SZ-RA SNP correlation is more nega-
tive in SNPs in immune-related pathways. To avoid mul-
tiple testing, we selected a single immune gene set based
on previous work using the Stahl GWAS results of Hu
et al.58 Using gene expression from 223 murine immune
cell types, they reported over-representation of RA-associ-
ated SNPs in genes expressed specifically in CD4þ ef-
fector memory T cells, with strongest over-representation
in genes expressed in the subcutaneous lymph node subset
named T.4Mem44h62l.LN.58 We selected the top 4000
genes expressed in the T.4Mem44h62l.LN cells to be in
the ‘T4Mem’ set. The arbitrary threshold of 4000 genes
generated an SNP set of about 10% of the total SNPs ana-
lysed. We tested if the T4Mem genes make an enriched
contribution to SNP heritabilities and the SNP correl-
ation, partitioning the coding/regulatory, DHS and in-
tronic partitions into T4Mem and non-T4Mem classes
(Supplementary Table 4, available as Supplementary data
at IJE online). As expected, there was a significant enrich-
ment for variance attributable to the T4Mem class for RA
(28% of the SNP heritability compared with only 11.5%
of SNPs, 2.5 fold enrichment, P¼ 2.0e-11). Interestingly,
there was also significant enrichment of variance attribut-
able to T4Mem regulatory SNPs in SZ (16% of SNP herit-
ability, P¼ 2.4e-04). We did not find evidence that SNPs
in this group of genes were more negatively correlated
than those in the rest of the genome, although the patterns
of correlations are difficult to interpret, and the size of
the standard errors means that the sample is underpow-
ered (Supplementary Table 4).
Benchmarking with epidemiological observations
We can benchmark our estimated SNP correlation between
RA and SZ of 0.046 relative to expectation from epi-
demiological data. Using the meta-analysis result that the
risk of RA in those with SZ is 29% of the risk in the
general population,1 we estimate that this implies a
phenotypic correlation between the disorders of 0.15
(equation 1; KSZ¼ 0.01 and KRA¼ 0.01, respectively,
KRAjSZ¼ 0.29*KRA). More recent epidemiological stud-
ies2,7 imply a substantially smaller negative phenotypic
correlation (0.05). Phenotypic correlation is considered
a reasonable benchmark for genetic correlation,59 and
Figure 3. Genomic partitioning analyses; (i) Percentage of SNP heritabil-
ity attributed to each functional annotation class for SZ and RA, com-
pared with the percentage of SNPs attributed to each class. Adjacent to
the bars are the P-values for H0: percentage of variation attributed to
annotation class ¼ percentage of SNPs attributed to the annotation
class; (ii) SNP correlation between SZ and RA based on annotation.
Estimates are from analyses using as the phenotype residuals after ad-
justing SNPs in the MHC region. When the MHC is included, the coding/
regulatory correlation is 0.174, s.e. 0.071, P¼ 0.0075.
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therefore our small negative estimate of the genetic correl-
ation is consistent with the epidemiological data.
However, the genetic relationship between SZ and RA is
complex. As an autoimmune disease, the MHC region con-
tains risk factors for RA which alone explain 5% of the
variance in liability to RA, whereas the most significant in-
dividual SNP association for SZ, also in the MHC region,
explains only 0.1% of variance in liability (ref60 and con-
sistent with Table 1 with and without MHC region). These
MHC risk alleles are positively correlated in SZ and RA,
although clearly the effect sizes are very different. In ana-
lyses in which we first removed the contribution to vari-
ance of the MHC region, the magnitude of negative
correlation between SZ and RA increased (0.065, s.e.
0.015, P¼ 0.015), and increased further still when con-
sidering only SNPs in coding and regulatory regions of the
genome (0.322, s.e. 0.115, P¼0.003), indicating that re-
gions of the genome other than the MHC region contribute
to the epidemiological observations.
Genotype x environment analysis
Although RA is well recognized as an immune disorder,
the contribution of immune activation to SZ is open to de-
bate (see Introduction). To add further insight to the com-
plex relationship between SZ and RA, we postulated that
if there is any interplay in risk for SZ between environmen-
tal risk factors associated with immune challenge and
genes that are relevant to the immune response, it is likely
to occur at the coding and regulatory regions. This is based
on the rationale that these are the sets of variants that both
capture the SNP heritability of RA (i.e. are likely to be
most enriched for genes with influences on immune activa-
tion) and are negatively correlated with SZ (i.e. are both
immune activation and SZ relevant). If our hypothesis is
correct, we predict that the apparent effect sizes in schizo-
phrenia at these loci will be greater in those exposed to a
relevant immune challenge than in those who are not.
Consequently, we predict that the negative correlation be-
tween SZ and RA will be larger at these loci in cases
exposed to an immune challenge. At present, our ability to
test this G x E hypothesis is limited by availability of sam-
ples that are both genetically informative and recorded for
environmental risks. We therefore sought a proxy for im-
mune challenge in SZ.
A robust epidemiological finding in SZ research is that
people with the disorder are more likely to be born in win-
ter or spring than summer or autumn61 (odds ratio 1.07,
95% CI 1.05–1.08, estimated from a meta-analysis of 27
studies62). Winter/spring birth is also associated with rec-
ognized immune-mediated disorders including RA.63
Candidate exposures underlying this finding include
seasonally varying factors such as prenatal vitamin D, or
maternal/fetal exposure to infections. Both factors can im-
pact on the immune system.64–66 In the absence then of dir-
ect measures of immune activation, we used season of
birth as our proxy measure; in doing so, we are aware this
proxy measure is only likely to be weakly correlated with
exposure and hence its use will adversely affect power.
Month of birth was only available for the SWE SZ sam-
ple. We selected quasi-independent SNPs associated at
P<0.05 and minor allele frequency> 0.05 (47 318 SNPs)
from the largest published schizophrenia meta-analysis.36
We next divided them into coding/regulatory (2820 SNPs,
6%) and non coding/regulatory sets. We undertook a bivari-
ate GREML analysis of the SWE datasets in which the two
traits were winter-born (January to April) vs non-winter
born SZ cases and controls; this division was justified by
studies using Swedish data.22 The correlation between win-
ter/non-winter born was significant for coding/regulatory
SNPs (0.56, s.e. 0.14, P¼ 0.0009) but not so for other SNPs
(0.95, s.e. 0.05, P¼0.15) (Supplementary Table 5, available
as Supplementary data at IJE online). To visualize this inter-
action, and to demonstrate that effects sizes of the coding/
regulatory SNP set are increased in the winter-born cohort,
we present the mean association OR for the different season
by annotation classes estimated in the SWE SZ sample
(Figure 4). We confirmed that results were robust to the P-
value threshold used for selection of associated SNPs
(Supplementary Table 6, available as Supplementary data at
IJE online) and we checked the seasonal trend by using slid-
ing window definitions of 4-month season definitions
(Supplementary Table 7, available as Supplementary data at
IJE online). The results are consistent with our G x E hy-
pothesis of immune-related disruption proxied by winter
birth, in concert with risk variants in coding/regulatory re-
gions increasing risk of schizophrenia.
Strengths and limitations
The strength of our methodological approach to explore the
genetic relationship between SZ and RA is that it is based
on genome-wide genotype data and uses independently col-
lected data for the two diseases studied. While under review,
two studies have investigated the relationship between SZ
and RA based partially67 or fully68 on GWAS summary
statistics; one reported a non-significant small positive rela-
tionship67 and the other a non-significant small negative re-
lationship.68 Use of genotype data is computationally more
demanding but is considered more definitive than methods
based on summary statistics,57 and such an approach is
needed when the relationship between the disorders is
benchmarked by a weak phenotypic correlation of 0.05 to
0.15. The results here indicate that there is a subset of
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genetic variants that are risk alleles for SZ and protective
for RA, and vice versa. Furthermore, as sample sizes in-
crease, more fine-scaled partitioning of variance by annota-
tion and genomic region will become possible and specific
variants involved will be identified. Our analyses indicate
that these pleiotropic loci are located in the coding/regula-
tory regions of the genome, hinting at directly functional
variants. Pleiotropy could help explain why common risk
variants are maintained in the population, since selection
operates on the net effect of fitness.
As limitations, we first note that cases and controls for
each disorder were not screened for the other disorder.
However, since both disorders are uncommon, the impact
is expected to be small. Second, we were unable to investi-
gate the relationship between SZ and seronegative RA be-
cause we found no evidence of SNP heritability for this
case group. An analysis of seronegative RA is of particular
interest since a recent epidemiological study found that
decreased risk of RA in relatives of those with SZ was only
apparent for seronegative RA.2 The stringent QC needed
for case-control GREML analyses may remove true sig-
nals38 and this may play a role in the seronegative samples
available here. Nonetheless, a lower SNP heritability for
seronegative RA vs seropositive RA is consistent with recent
estimates of heritability based on family data,9 and also con-
sistent with smaller OR for seronegative genetic associations
than for seropositive associations.13,69 A SNP correlation of
0.98, s.e. 0.165, was estimated in a Han Chinese sample;69
we note that the proportion of seronegative cases in this
study was high (519/952¼ 55%) and any misclassification
could serve to inflate the correlation.70 Third, the non-avail-
ability of sex chromosome data meant that we could only
explore sex differences based on autosomal SNPs. Fourth,
we did not have the power to break down the signal attrib-
uted to coding/regulatory regions into more finely defined
functional categories. Last, given the limitations on the data
available to test the G x E hypothesis, alternative explan-
ations for our results cannot be excluded.
Discussion
In summary, we have applied a mixed linear model method
to estimate the genetic correlation between RA and SZ.
Epidemiological evidence has demonstrated decreased
prevalence rates of RA in SZ cases, consistent with a pheno-
typic correlation of liabilities of up to 0.15. We show that
there is a small but significant negative correlation across
the genome and the signal is stronger for SNPs annotated as
coding and regulatory. Given that RA is an immune-related
disorder and that a role for immune activation has long
been hypothesized for SZ, a negative genetic correlation
could imply that variants in immune response pathways
have different roles in different tissues and/or in response to
different challenges. The immune activation hypothesis of
SZ is partly founded on an increased risk for SZ associated
with month of birth. Our hypothesis that increased effect
sizes for SZ-associated SNPs in the coding/regulatory SNP
set for a winter-born case-control set was supported by our
analyses, although other explanations for these results may
be possible. Most importantly, if the complexity of SZ is to
be unraveled, then data sets that are informative for both
genetic and environmental risk factors are essential. Since
SZ is an adult-onset disorder, and yet perinatal and child-
hood experience, especially infections, are known environ-
mental risk factors, then prospective gathering of data in
nationally accessible repositories is needed.
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